<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02259361</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-13-0380-AA-CTIL</org_study_id>
    <nct_id>NCT02259361</nct_id>
  </id_info>
  <brief_title>Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS</brief_title>
  <official_title>Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of sustained-release oral dalfampridine in the treatment of
      upper limb deficits in people with multiple sclerosis (MS). In this double-blind randomized
      pilot study half of participants will dalfampridine, while the other half will receive a
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dalfampridine (ampyra), a drug with a mechanism for symptomatic management of MS among blocks
      potassium channels on demyelinated neurons, allows normal electrical conduction.

      Dalfampridine has recently been found to be associated with improvements in visual function,
      strength, ambulation, fatigue, and endurance in individuals with MS.

      Although this medication has a widespread effect, its influence on upper extremity function
      has never been investigated in a double blind randomized case control study.

      Following the fact that during the disease course, approximately 3 out of 4 multiple
      sclerosis patients encounter upper limb dysfunction the primary objective of this study will
      be to investigate the efficacy of sustained-release oral dalfampridine on upper extremity
      function in patients with MS.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nine-Hole Peg Test</measure>
    <time_frame>Changes in the Nine-Hole Peg Test from Baseline to end of Second week</time_frame>
    <description>The Nine-Hole Peg Test is a brief, standardized, quantitative test of upper extremity function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nine-Hole Peg Test</measure>
    <time_frame>Changes in the Nine-Hole Peg Test from Baseline to end of first week</time_frame>
    <description>The Nine-Hole Peg Test is a brief, standardized, quantitative test of upper extremity function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nine-Hole Peg Test</measure>
    <time_frame>Changes in the Nine-Hole Peg Test from end of second week to follow up 2-weeks after end of intervention phase</time_frame>
    <description>The Nine-Hole Peg Test is a brief, standardized, quantitative test of upper extremity function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Box and Block test</measure>
    <time_frame>Changes in the Box and Block Test from Baseline to end of Second week</time_frame>
    <description>The box and blocks test (BBT) examines manual dexterity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Box and Block test</measure>
    <time_frame>Changes in the Box and Block Test from Baseline to end of first week</time_frame>
    <description>The box and blocks test (BBT) examines manual dexterity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Box and Block test</measure>
    <time_frame>Changes in the Box and Block Test from end of second week to follow up 2-weeks after end of intervention phase</time_frame>
    <description>The box and blocks test (BBT) examines manual dexterity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isometric grip force and motor fatigue</measure>
    <time_frame>Changes in the Isometric grip force and motor fatigue tests from baseline to end of Second week</time_frame>
    <description>Peak isometric grip force (in NM) and isometric fatigue index will be determined by a hand-held dynamometer (Biometrics Ltd., USA). The hand-held dynamometer is a medical device used to assess grip strength in functional assessment and in initial and ongoing evaluation of patients with hand dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isometric grip force and motor fatigue</measure>
    <time_frame>Changes in the Isometric grip force and motor fatigue tests from baseline to end of first week</time_frame>
    <description>Peak isometric grip force (in NM) and isometric fatigue index will be determined by a hand-held dynamometer (Biometrics Ltd.,USA). The hand-held dynamometer is a medical device used to assess grip strength in functional assessment and in initial and ongoing evaluation of patients with hand dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Isometric grip force and motor fatigue</measure>
    <time_frame>Changes in the Isometric grip force and motor fatigue tests from end of second week to follow up 2-weeks after end of intervention phase</time_frame>
    <description>Peak isometric grip force (in NM) and isometric fatigue index will be determined by a hand-held dynamometer (Biometrics Ltd.,USA). The hand-held dynamometer is a medical device used to assess grip strength in functional assessment and in initial and ongoing evaluation of patients with hand dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory evaluation</measure>
    <time_frame>Changes in the Sensory evaluation Test from Baseline to end of Second week</time_frame>
    <description>The two-point discrimination test will be used to determine tactile sensation. Light-touch and pressure-sensation thresholds will be determined using monofilaments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory evaluation</measure>
    <time_frame>Changes in the Sensory evaluation Test from Baseline to end of first week</time_frame>
    <description>The two-point discrimination test will be used to determine tactile sensation. Light-touch and pressure-sensation thresholds will be determined using monofilaments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory evaluation</measure>
    <time_frame>Changes in the Sensory evaluation Test from end of second week to follow up 2-weeks after end of intervention phase</time_frame>
    <description>The two-point discrimination test will be used to determine tactile sensation. Light-touch and pressure-sensation thresholds will be determined using monofilaments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient rating scale - Disabilities of the Arm, Shoulder and Hand (DASH)</measure>
    <time_frame>Changes in the DASH Test from Baseline to end of Second week</time_frame>
    <description>The DASH (http://www.dash.iwh.on.ca/) has 30 items grouped into one scale aiming to measure 'physical function and symptoms' in people with disorders of the upper limb.15 Items are scored from 1 (no difficulty) to 5 (unable). A total 'disability/symptom' score is generated by summing items, and averaging to produce a mean item score between 1 and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient rating scale - Disabilities of the Arm, Shoulder and Hand (DASH)</measure>
    <time_frame>Changes in the DASH Test from Baseline to end of first week</time_frame>
    <description>The DASH (http://www.dash.iwh.on.ca/) has 30 items grouped into one scale aiming to measure 'physical function and symptoms' in people with disorders of the upper limb.15 Items are scored from 1 (no difficulty) to 5 (unable). A total 'disability/symptom' score is generated by summing items, and averaging to produce a mean item score between 1 and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient rating scale - Disabilities of the Arm, Shoulder and Hand (DASH)</measure>
    <time_frame>Changes in the DASH Test from end of second week to follow up 2-weeks after end of intervention phase</time_frame>
    <description>The DASH (http://www.dash.iwh.on.ca/) has 30 items grouped into one scale aiming to measure 'physical function and symptoms' in people with disorders of the upper limb.15 Items are scored from 1 (no difficulty) to 5 (unable). A total 'disability/symptom' score is generated by summing items, and averaging to produce a mean item score between 1 and 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Sustained-release oral dalfampridine, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sustained-release oral dalfampridine</intervention_name>
    <description>One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Prolonged-release Fampridine</other_name>
    <other_name>Ampyra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Active comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must have the ability to understand the purpose and risks of the study
             provide a signed and dated informed consent and authorize confidential health
             information to be examined in accordance with national and local subject privacy
             regulations.

          2. The patient must have been diagnosed with clinically definite MS, at the time of
             informed consent.

          3. The patient must be between 18-70 years of age, inclusive, at the time of informed
             consent.

          4. The patient must have scored between 50 and 90 on the upper limb Motricity Index test,
             at the time of informed consent. This test evaluates strength during three essential
             movements (pinch grasp, elbow flexion and shoulder abduction). The selected score
             range criteria determine patients who suffer a moderate decline in function abilities
             of the upper limb.

        Exclusion Criteria:

          1. Onset of multiple sclerosis exacerbation within 60 days of screening.

          2. History of seizures or evidence of epileptic form activity found on a screened
             electroencephalogram.

          3. Changes in concomitant medications to avoid related changes in multiple sclerosis
             symptoms during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anat Achiron, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Multiple Sclerosis Center, Sheba Medical Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shlomo Noy, MD, PhD</last_name>
    <phone>972-3-5305284</phone>
    <email>Shlomo.noy@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alon Kalron, PhD</last_name>
    <phone>972-2-2436839</phone>
    <email>alkalron@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Multiple Sclerosis Center</name>
      <address>
        <city>Tel-hashomer</city>
        <state>Ramat-gan</state>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alon Kalron, PhD</last_name>
      <phone>972-52-2436839</phone>
      <email>alkalron@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Johansson S, Ytterberg C, Claesson IM, Lindberg J, Hillert J, Andersson M, Wid√©n Holmqvist L, von Koch L. High concurrent presence of disability in multiple sclerosis. Associations with perceived health. J Neurol. 2007 Jun;254(6):767-73. Epub 2007 Apr 2.</citation>
    <PMID>17401746</PMID>
  </reference>
  <reference>
    <citation>Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006 Jul;111(1):224-59. Epub 2006 Feb 9. Review.</citation>
    <PMID>16472864</PMID>
  </reference>
  <reference>
    <citation>Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.</citation>
    <PMID>19249634</PMID>
  </reference>
  <reference>
    <citation>van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol. 1992 Aug;32(2):123-30.</citation>
    <PMID>1510353</PMID>
  </reference>
  <reference>
    <citation>Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology. 1991 Sep;41(9):1344-8.</citation>
    <PMID>1891078</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>October 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2014</study_first_posted>
  <last_update_submitted>October 5, 2014</last_update_submitted>
  <last_update_submitted_qc>October 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

